DSpace logo

Please use this identifier to cite or link to this item: http://dspace.bits-pilani.ac.in:8080/jspui/xmlui/handle/123456789/13224
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMahesh, R.-
dc.date.accessioned2023-11-22T10:56:57Z-
dc.date.available2023-11-22T10:56:57Z-
dc.date.issued2016-
dc.identifier.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345311/-
dc.identifier.urihttp://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13224-
dc.description.abstractAlteration in the serotonin leads to the psychological illness, such as depression, anxiety, schizophrenia, eating disorders, obsessive-compulsive disorder, panic disorders and migraines. The objective of the current study was to investigate the antidepressant and anxiolytic activities of N-(pyridin-3-yl) quinoxalin-2-carboxamide (QCF-21), a novel 5-HT3 receptor antagonist in preclinical models of depression and anxiety.en_US
dc.language.isoenen_US
dc.publisherIJMRen_US
dc.subjectPharmacyen_US
dc.subjectAnxietyen_US
dc.subjectBehavioural testsen_US
dc.subjectDepressionen_US
dc.subjectN-(pyridin-3-yl) quinoxalin-2-carboxamideen_US
dc.subjectNovel 5-HT3 antagonisten_US
dc.subjectSerotonin systemen_US
dc.titleAntidepressant & anxiolytic activities of N-(pyridin-3-yl) quinoxalin-2-carboxamide: A novel serotonin type 3 receptor antagonist in behavioural animal modelsen_US
dc.typeArticleen_US
Appears in Collections:Department of Pharmacy

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.